Compare NTRB & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRB | CELU |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | 3 | 123 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4M | 35.2M |
| IPO Year | N/A | N/A |
| Metric | NTRB | CELU |
|---|---|---|
| Price | $3.53 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 8.7K | ★ 147.2K |
| Earning Date | 05-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.21 | $0.71 |
| 52 Week High | $11.68 | $4.35 |
| Indicator | NTRB | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 39.14 |
| Support Level | $3.44 | $0.71 |
| Resistance Level | $3.69 | $1.46 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 79.21 | 23.73 |
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.